The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline.
The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics.
The AMR Action Fund brings together a broad alliance of industry and non-industry stakeholders, including philanthropies, development banks, and multilaterals, to encourage governments to create market conditions that enable sustainable investment in the pipeline and will strengthen and accelerate the research and development of antibiotics through investment and provision of industry resources and expertise to biotechnology companies.
Learn more about the fund
Learn more about BIO’s work on AMR at WorkingToFightAMR.org.